Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

BACKGROUND. Vemurafenib has been approved for the treatment of patients with advanced BRAF(V600E)-mutant melanoma. This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs) that occur in vemurafenib-treated patients, including cutaneou...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lacouture, Mario E., Duvic, Madeleine, Hauschild, Axel, Prieto, Victor G., Robert, Caroline, Schadendorf, Dirk, Kim, Caroline C., McCormack, Christopher J., Myskowski, Patricia L., Spleiss, Olivia, Trunzer, Kerstin, Su, Fei, Nelson, Betty, Nolop, Keith B., Grippo, Joseph F., Lee, Richard J., Klimek, Matthew J., Troy, James L., Joe, Andrew K.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Melanoma and Cutaneous Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607529/
https://ncbi.nlm.nih.gov/pubmed/23457002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0333
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados